GlassScriptPhysician profile
Stuart A Glasser
NPI 1821042862
$13,308.61
in general payments reported to CMS, 2019-2025
38 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 76% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $1,617 · 2021: $1,607 · 2022: $2,337 · 2023: $2,094 · 2024: $1,974 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,797 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,796.81 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,042.66 | 2019-2025 | |
| Janssen Biotech, INC. | $1,688.68 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $1,258.62 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $1,081.52 | 2019-2025 | |
| Pfizer INC. | $633.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $613.03 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $541.84 | 2020-2025 | Winlevi |
| Genzyme Corporation | $463.33 | 2019-2025 | |
| Ucb, INC. | $461.40 | 2019-2025 | Bimzelx, Cimzia |
| Merz North America, INC. | $368.81 | 2019-2024 | Xeomin |
| Galderma Laboratories, L.P. | $295.36 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $290.31 | 2019-2025 | Adbry |
| Prugen, INC. Pharmaceuticals | $284.00 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $232.37 | 2023-2025 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $210.50 | 2019-2025 | Dupixent |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $202.69 | 2019-2025 | Taltz, Ebglyss |
| Biofrontera INC. | $163.08 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $162.34 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $160.76 | 2019-2025 | |
| Incyte Corporation | $156.09 | 2021-2025 | Opzelura |
| Celgene Corporation | $144.04 | 2019 | |
| Journey Medical Corporation | $143.18 | 2019-2024 | |
| Dermavant Sciences, INC. | $140.64 | 2022-2024 | Vtama |
| Teva Pharmaceuticals USA, INC. | $83.17 | 2019 | |
| Epi Health, LLC | $64.82 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $62.36 | 2023-2025 | Zoryve |
| Almirall LLC | $61.40 | 2019-2022 | |
| Genentech USA, INC. | $57.75 | 2019-2023 | Xolair |
| Vyne Pharmaceuticals INC. | $56.53 | 2020-2021 | |
| Dermira, INC. | $31.39 | 2019 | |
| Mission Pharmacal Company | $30.44 | 2020-2021 | |
| Encore Dermatology INC. | $23.84 | 2020 | |
| Sandoz INC. | $19.50 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.73 | 2020 | |
| Merck Sharp & Dohme LLC | $15.60 | 2019 | |
| Aclaris Therapeutics, INC. | $15.55 | 2019 | |
| Strata Skin Sciences, INC. | $14.55 | 2025 | Xtrac |
| Dusa Pharmaceuticals, INC. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Glasser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.